Table 1 Expression of CD163 or CD47 in PanNETs and their associations with clinicopathologic characteristics
From: CD47 expression and CD163+ macrophages correlated with prognosis of pancreatic neuroendocrine tumor
|  | Number of patients | CD163 positive macrophages (mean ± SD) | P value | CD47 H- score (mean ± SD) | P value |
|---|---|---|---|---|---|
Age (Years) | |||||
 ≥ 65 | 24 | 82.53 ± 8.54 | 0.041 | 134.6 ± 8.89 | 0.048 |
 < 65 | 23 | 59.38 ± 6.81 |  | 163.7 ± 11.35 |  |
Gender | |||||
 Male | 30 | 70.99 ± 6.64 | 0.962 | 159.5 ± 10.21 | 0.055 |
 Female | 17 | 71.57 ± 10.81 |  | 130.0 ± 8.27 |  |
Tumor size (cm) | |||||
 ≥ mean size (3.2) | 20 | 73.47 ± 10.69 | 0.735 | 135.8 ± 12.01 | 0.130 |
 < ≥mean size | 27 | 69.52 ± 6.15 |  | 158.5 ± 9.09 |  |
Ki 67 | |||||
 ≥ 3% | 28 | 71.30 ± 8.01 | 0.983 | 140.2 ± 10.00 | 0.159 |
 < 3% | 19 | 71.05 ± 7.97 |  | 161.6 ± 10.53 |  |
Mitosis | |||||
 ≥ 2/10hpf | 28 | 79.51 ± 8.21 | 0.076 | 137.3 ± 9.47 | 0.059 |
 < 2/10hpf | 19 | 58.96 ± 6.49 |  | 165.8 ± 11.05 |  |
Tumor grade | |||||
 G1 | 17 | 68.24 ± 7.95 | 0.896 | 160.6 ± 11.46 | 0.268 |
 G2 | 25 | 67.67 ± 7.27 |  | 146.8 ± 10.84 |  |
 G3 | 5 | 76.70 ± 24.23 |  | 119.0 ± 16.61 |  |
Pathologic stage (AJCC 8th) | |||||
 1 | 12 | 61.12 ± 6.42 | 0.061 | 165.4 ± 13.28 | 0.185 |
 2 | 21 | 69.99 ± 9.18 |  | 147.4 ± 10.35 |  |
 3 | 14 | 81.67 ± 12.07 |  | 136.8 ± 15.74 |  |